Dr. Agarwals Health Care Posts Robust Q1 FY27 Growth

Revenue from operations ₹614 Cr, PAT ₹55 Cr.

Reader Takeaway: Strong growth momentum and margin expansion are positive, while future capex needs are a watch point.

What just happened

Dr. Agarwals Health Care announced its financial results for the quarter ended June 30, 2026 (Q1'FY27), showcasing significant year-on-year growth. Revenue from operations increased by 26.0% to ₹614 crore, while Profit After Tax (PAT) surged by 44.6% to ₹55 crore.

Why this matters

These results indicate strong demand for the company's services and successful execution of its expansion strategy. The growth in revenue and profit, coupled with a slight improvement in EBITDA margins to 28.5%, suggests efficient operations and scalability.

The backstory

Dr. Agarwals Health Care has been steadily expanding its network of eye care facilities. As of June 30, 2026, the company operates 304 facilities across India and internationally, a testament to its hub-and-spoke operational model which supports scalable growth.

What changes now

The company plans to continue its aggressive expansion, with intentions to add 12 new facilities in Q2'FY27 and another 30 in the second half of FY27. This proactive approach aims to further strengthen its market presence and leverage brand trust.

Risks to watch

Management has indicated a potential need for higher capital expenditure in the future to upgrade technology and equipment to stay competitive in the evolving healthcare landscape.

Peer comparison

While specific peer performance data for Q1 FY27 is not detailed in the filing, Dr. Agarwals' double-digit revenue growth and margin expansion appear positive within the healthcare services sector.

Context metrics (time-bound)

In Q1'FY27, Dr. Agarwals Health Care performed over 91,000 surgeries and served more than 882,000 patients. The company maintained a net cash positive position, with net debt (including cash and equivalents) at ₹62 crore, down from ₹278 crore in Q1'FY26.

What to track next

Investors will be keen to monitor the successful commissioning and ramp-up of the 42 planned new facilities in FY27. The company's ability to manage capital expenditure for technological upgrades while sustaining profitability will also be a key factor.